American Academy of Allergy, Asthma & Immunology

Barzolvolimab therapy resulted in significant improvement of cold urticaria (ColdU) following 20 weeks of treatment.

Pooled REMIX-1/-2 data show remibrutinib reduced CSU activity within 12 hours, with greater UAS improvements vs placebo through day 7.

Cogent Biosciences previously submitted an NDA for bezuclastinib at the end of 2025.

Akin discussed how avapritinib continues to demonstrate its benefit in indolent systematic mastocytosis.

At AAAAI 2026, Han reports pooled ANCHOR data showing depemokimab improved nasal symptoms, QoL, and cut rescue interventions.

Interim phase 3 APeX-P data presented at AAAAI 2026 show sustained 48-week reductions in moderate and severe HAE attacks with oral berotralstat in children aged 2–11 years.

Nguyen discussed how her study findings can help alleviate inhaled corticosteroid hesitancy for families.

Early gut microbiome changes in c-section infants linked to food sensitization at 12 months, highlighting a potential critical intervention window.

Trial data show early microbiome shifts after vaginal microbial transfer in cesarean-delivered infants, with differences in food sensitization at 12 months.

Nguyen emphasized the safety of inhaled corticosteroids vs SABA-only therapy in pediatric asthma.

HLA-A*32:01 carrier screening may identify patients at elevated risk for lamotrigine-induced eosinophilia and systemic symptoms, Krantz says at AAAAI 2026.

A new study stratified patients by longitudinal BEC patterns to assess whether variability in eosinophil levels influences response.

Prospective case-control data presented at AAAI 2026 demonstrate a 12-fold increased odds of DRESS among lamotrigine-treated HLA-A*32:01 carriers.

Retrospective analysis presented at AAAAI 2026 found 12%–15% risk reductions in asthma exacerbations over 3 years among patients without diabetes with overweight and obesity.

Sicherer discussed how the study might shift clinical thinking in pediatric food allergy.

Once-daily VTAMZA delivers week-one sleep gains and lasting itch control in atopic dermatitis, with safety consistent across studies.

Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years

Sicherer discussed how findings from CAFETERIA may inform treatment decisions for children with high-threshold allergy.

AAAAI 2026 showcases high-impact clinical trials and innovative sessions, 5 of which are highlighted below.

Hoyte discussed findings from a post hoc analysis of the phase 3 NAVIGATOR study.

Chambliss also discussed other research she is working on looking to understand effects on children with asthma.

Pongdee also discussed the changing treatment landscape for indolent systemic mastocytosis and questions that will need to be answered in the field.

At AAAAI 2025, HCPLive spoke with Craig about recognizing and treating hereditary angioedemia.

Lipworth shared findings from 2 studies that he presented data from at the AAAAI/WAO Joint Congress.

Cianferoni discusses how pollen food allergy syndrome contributes to eosinophilic esophagitis (EoE) and potential management strategies.

At AAAAI 2025, Cianferoni described molecular mechanisms of pollen food allergy syndrome.

HCPLive spoke with Anagnostou at AAAAI on how to determine what food allergy treatment patients should undergo.

Chambliss and colleagues found a 1% increase in asthma-related emergency department visits per unit of distance to semiconductor fabrication plants.

At AAAAI, Golden discussed when to test for insect sting allergies, the role of venom immunotherapy, and the potential impact of epinephrine nasal spray.

At AAAAI 2025, David Golden, MD, discussed when to test for insect sting allergies, the role of mast cell disorders, and updated guidelines for all ages.